Mavodelpar

立即咨询

Mavodelpar

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1604815-32-8

REN001
HPP593

Mavodelpar (REN001) 是一种选择性的PPARδagonist。Mavodelpar 抑制肾小球损伤和肾纤维化。Mavodelpar 可用于原发性线粒体肌病 (PMM) 和长链脂肪酸氧化障碍 (LC-FAOD) 的研究。

生物活性

Mavodelpar (REN001) is a selectivePPARδagonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)^[1].

体内研究
(In Vivo)

Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平^[1]。

Animal Model:	Male and female B6129SF1-Col4a3^-/-mice^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age
Result:	Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.

分子量

537.55

Formula

C₃₁H₂₉FNNaO₅

CAS 号

1604815-32-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.